The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 15 - 2024 |
doi: 10.3389/fmicb.2024.1463005
This article is part of the Research Topic New Insights into The Role of Lactic Acid Bacteria in the Regulation of Gut Microbiota View all 4 articles
Berberine attenuates TNBS-induced colitis in mice by improving the intestinal microbiota
Provisionally accepted- 1 Department of Gastroenterology, Beijing Anzhen Hopital, Capital Medical University, Beijing, China
- 2 Department of Basic Medicine, Qinghai University Medical College, Xining, Qinghai Province, China
- 3 Department of Gastroenterology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
- 4 Qinghai University Medical College, Xining, Qinghai Province, China
- 5 Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Objective To investigate the effects of berberine (BBR) as a treatment on intestinal microecological alterations and enteritis in mice produced by TNBS. Methods There were seven mice per group: seven in the healthy group (Ctrl), seven in the TNBS-induced enteritis group (TNBS), and seven in the berberine treatment group (BBR). The mice were weighed, slaughtered after seven days, and subjected to high-throughput intestinal microecological analysis by Illumina, as well as haematological detection and imaging evaluation of colon pathology.Results The alterations in colon length, immune cell subpopulations, inflammatory factors, and intestinal microecology of mice induced by BBR were refined using a battery of experiments and observations. According to intestinal microecological studies, BBR can increase the number of bacteria, including Lactobacillus, Verrucomicrobia, Bacteroides, and Akkermansia muciniphila. Conclusion BBR has a therapeutic effect on TNBS-induced colitis in mice, which is associated with modifications in immune cell subpopulations and intestinal microecology. It also offers a viable approach as a prospective probiotic (like Akkermansia muciniphila) to IBD therapy in clinical settings.
Keywords: Berberine, Intestinal microecology, Colitis, Probiotics, Akkermansia muciniphila
Received: 11 Jul 2024; Accepted: 12 Aug 2024.
Copyright: © 2024 Li, Yin, Xie, Zeng, Song, Yang, Zhang, Chen, Wei, Wang, Gu, Li, An and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chao Li, Department of Gastroenterology, Beijing Anzhen Hopital, Capital Medical University, Beijing, 100029, China
Changpeng Xie, Department of Basic Medicine, Qinghai University Medical College, Xining, Qinghai Province, China
Jin Zeng, Department of Basic Medicine, Qinghai University Medical College, Xining, Qinghai Province, China
Guibin Yang, Department of Gastroenterology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China
Jinglei Zhang, Department of Basic Medicine, Qinghai University Medical College, Xining, Qinghai Province, China
Siai Chen, Qinghai University Medical College, Xining, Qinghai Province, China
Panjian Wei, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Ziyu Wang, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Meng Gu, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Wei Li, Department of Gastroenterology, Beijing Anzhen Hopital, Capital Medical University, Beijing, 100029, China
Juan An, Department of Basic Medicine, Qinghai University Medical College, Xining, Qinghai Province, China
Yuanming Pan, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.